Corpus Intelligence IC Memo — MIZELL MEMORIAL HOSPITAL 2026-04-28 08:31 UTC
IC Memo — MIZELL MEMORIAL HOSPITAL
Investment Committee Memorandum | AL | 45 beds | Grade C | EBITDA uplift $1.6M
🛡️ Public data only — no PHI permitted on this instance.
INVESTMENT COMMITTEE MEMORANDUM  ·  CCN 010007

MIZELL MEMORIAL HOSPITAL

LOCATIONCOVINGTON, AL·BEDS45·AS OFApril 28, 2026
C
INVESTABILITY
EBITDA BridgeData Room

1. Target Overview & Investment Thesis

MIZELL MEMORIAL HOSPITAL is a 45-bed under-performing / distressed in COVINGTON, AL with $21.4M in net patient revenue and a -16.8% operating margin. The hospital serves a payer mix of 43.2% Medicare, 10.0% Medicaid, and 46.9% commercial.

Thesis: Turnaround. Our ML models identify $1.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -16.8% to -9.4% (+736bps).

Net Revenue HCRIS$21.4M
Current EBITDA COMPUTED$-3.6M
Operating Margin COMPUTED-16.8%
Occupancy HCRIS36.6%
Revenue / Bed COMPUTED$476K
Net-to-Gross HCRIS32.2%
Distress Probability ML54.5%

2. Market Context & Competitive Position

115
AL Hospitals
-8.5%
State Median Margin
58
Comparable Hospitals

AL has 115 Medicare-certified hospitals with a median operating margin of -8.5%. The target's margin of -16.8% places it below the state median. Among 58 size-comparable peers (22-90 beds), the median margin is -15.3%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (22-90), prioritizing same-state peers. 58 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MIZELL MEMORIAL HOSPITAL (Target)AL45$21.4M-16.8%
ATHENS LIMESTONEAL66$88.9M-20.9%
RUSSELL MEDICAL CENTERAL45$75.3M-14.8%
JACK HUGHSTON MEMORIAL HOSPITAAL47$75.2M6.5%
EASTPOINTE HOSPITALAL66$56.6M-50.0%
NORTH BALDWIN INFIRMARYAL35$55.3M-3.3%
PRATTVILLE BAPTIST HOSPITALAL55$53.5M-16.2%
HIGHLANDS MEDICAL CENTERAL45$45.9M-30.2%
ENCOMPASS HEALTH REHABILITATIOAL85$42.1M17.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$449K+210bp18mo
Cost to Collect4.5%2.5%$428K+200bp12mo
Denial Rate Reduction12.0%6.5%$424K+198bp12mo
A/R Days Reduction5200.0%3800.0%$260K+122bp9mo
Clean Claim Rate88.0%96.0%$14K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$449K
Cost to Collect
$428K
Denial Rate Reduction
$424K
A/R Days Reduction
$260K
Clean Claim Rate
$14K
Total EBITDA Uplift$1.6M
Current EBITDA$-3.6M
+ RCM Uplift+$1.6M
Pro Forma EBITDA$-2.0M
Current Margin-16.8%
Pro Forma Margin-9.4%
WC Released (1x)$821K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-5.5M$-7.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-5.5M$-10.5M0.00x-100.0%
Bull Case9.0x11.0x$-5.0M$-7.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-5.0M$-9.2M0.00x-100.0%
Bear Case11.0x10.0x$-6.1M$-14.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-6.1M$-17.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 54.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 58 hospitals with 22-90 beds
  • Same-state prioritization (n=59)
  • Comp margins: P25=-26.6% / P50=-15.3% / P75=1.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 28, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.